14 CostertonJ
2023;172:113594 Hoyles L, Snelling T, Umlai UK, Nicholson JK, Carding SR, Glen RC, McArthur S
Date of Opening: Clearly mark the date the vial was first punctured on the vial label
Although dapagliflozin and canagliflozin demonstrate cardiorenal protective effects in clinical settings, systemic NRF2 activation may disrupt physiological redox homeostasis
Why this trial matters: First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM Potential new standard of care as early as second-line Demonstrates deep responses, high MRD-negativity, and durable outcomes First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation
